Categories: News

Psychedelic Healthcare Innovation: PsiloThera Announces Launch of Quantum Technology Drug Development Program

HENDERSON, Nev., July 30, 2021 /PRNewswire/ — PsiloThera, Inc. is a pioneering Psychedelic Healthcare Innovation & Life Sciences Company developing Psilocybin (“Magic Mushroom”) based Drugs and Therapies proudly announces the launch of its Quantum Technology Drug Development Program.

“Quantum Technology could ultimately change the way that Humans digest supplements, medications and nutrients.”

PsiloThera’s Clinical Focus is the Treatment of Mental Illnesses including: Depression, Anxiety, PTSD, Eating Disorders & Addictions and Cognitive Diseases & Neurological Disorders such as Alzheimer’s, Dementia and Autism.

PsiloThera’s specialized treatment programs will provide care for Vets, 1st Responders & Patients with Treatment Resistant Mental Illnesses.

PsiloThera CEO, John Atanasio states,”PsiloThera is among the first companies focused on developing novel therapeutics by deploying Quantum Technology that can collect and send materials through organic devices.”

“PsiloThera’s strategy is to have its products lead the future of energy-based nutrients and medication delivery systems.”  “Quantum technology may lead to advances that could ultimately change the way that Humans digest supplements, medications and nutrients.”

“Our Quantum Technology Advisors projects that the technology projects to deliver significant improvements in areas  of Pharmaceutical dispensing issues and adverse effects.”

“Quantum Technology may lead to significant reductions in drug development time and costs, giving PsiloThera a possible major competitive advantage if that were to prove true”

The Journal of American Medical Association- “JAMA PSYCHIATRY” reported in a 2020 study that a treatment of Psilocybin “Magic Mushrooms” works much better than usual anti-depressant medications.

PsiloThera’s outstanding battle tested management team will operate the Company’s  vertical business model  which includes; Fungi Grow, Research & Development, Drug Development, Tele-Mental Health Platform and PsiloThera Treatment Centers.

PsiloThera just launched a Crowdfund Campaign @  www.startengine.com/psilothera 

Start Engine’s spokesperson is non-other than Shark Tank’s TV Show Personality, “Mr. Wonderful” Kevin O’Leary.

Source & Contacts: PsiloThera Inc.   john@psilothera.com    sara@startengine.com 

View original content to download multimedia:https://www.prnewswire.com/news-releases/psychedelic-healthcare-innovation-psilothera-announces-launch-of-quantum-technology-drug-development-program-301345163.html

SOURCE PsiloThera Inc.

Staff

Recent Posts

Daily Fit Notes Rolls Out Affordable Fitness Solutions for the Modern Lifestyle

Daily Fit Notes, founded by Justin Brey in New York, launches a text-based subscription fitness…

1 day ago

WillowWood Rebrand by DD.NYC Wins Gold Anthem Award for Product and Innovation in 2024 Rebrand

MT. STERLING, Ohio, Dec. 20, 2024 /PRNewswire/ -- WillowWood, a global leader in prosthetic solutions,…

1 day ago

Quantum Biopharma Announces Closing of Second Tranche

TORONTO, ON / ACCESSWIRE / December 20, 2024 / Quantum BioPharma Ltd. (NASDAQ:QNTM)(CSE:QNTM)(FRA:0K91) ("Quantum BioPharma"…

2 days ago

Glow Lifetech Announces Completion of Final Payment under Swiss Pharma Share Exchange Agreement and Debt Settlement

Toronto, Ontario--(Newsfile Corp. - December 20, 2024) - Glow Lifetech Corp. (CSE: GLOW) (OTC Pink:…

2 days ago

Bloom Burton & Co. Inc. Announces Changes to Holdings in Satellos Bioscience Inc.

Toronto, Ontario--(Newsfile Corp. - December 20, 2024) - Bloom Burton & Co. Inc. (Bloom Burton)…

2 days ago